Browse the evidence

Youth who achieved 5-6 goals had a higher insulin sensitivity (8.5 ± 4.3 mg/kg/min) compared to those who met 0-3 goals (5.2 ± 3.4 mg/kg/min, P = .003).

Practitioners should encourage adolescents with type 1 diabetes to meet ADA/ISPAD goals to improve insulin sensitivity.

Two days of recovery with optimal energy availability (OEA) partially restored performance but did not fully recover it to the level of the OEA group.

Recovery strategies should include optimal energy availability to aid performance recovery after low energy phases.

The intensive lifestyle intervention may need to be sustained to reduce long-term health care spending.

Practitioners should consider the importance of ongoing support for lifestyle interventions to maintain benefits.

Resistance-trained individuals are capable of high absolute RIR accuracy when predicting 1 and 3 RIR on the barbell bench press exercise.

Practitioners can use RIR prescriptions to effectively gauge proximity to failure during resistance training.

High raw and absolute mean RIR accuracy for 1-RIR and 3-RIR predictions were observed.

The observed accuracy metrics can help inform training protocols.

Research over the last 3 decades has demonstrated the utility of GLP-1 receptor signaling for weight loss.

Long-term research supports the use of GLP-1 receptor signaling in weight loss strategies.

Tirzepatide is approved for the management of type 2 diabetes.

Healthcare providers can consider tirzepatide as a treatment option for patients with type 2 diabetes.

The treatment landscape for glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is evolving.

Practitioners should stay updated on the evolving treatments for diabetes management.

There were small but statistically significant regains in waist circumference between 2 and 12 months for both maintenance diets.

Practitioners should be aware of potential waist circumference regain when implementing maintenance diets.

GLP-1 receptor agonists have shown early evidence of cardiovascular benefits in obese patients.

GLP-1 RAs may also be beneficial for cardiovascular health in obese patients.

Obesity increases stress throughout the musculoskeletal system and carries a higher risk for the development of osteoarthritis and various other musculoskeletal conditions.

Healthcare providers should consider the musculoskeletal risks associated with obesity when treating patients.

Obesity is associated with increased risk of complications in patients undergoing total joint arthroplasty.

Surgeons should be aware of the increased risks when treating obese patients in joint surgeries.

The metabolic changes induced by GLP-1 agonists can impact adipose and muscle tissue, leading to changes in facial contour and overall appearance.

Understanding these metabolic changes can help practitioners manage patient expectations regarding facial aesthetics.

Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).

Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.

Tirzepatide was more efficacious in younger, male patients of White ethnicity.

Treatment strategies may need to be tailored based on demographic factors for optimal outcomes.

Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).

Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.

A high body mass index is one of the strongest risk factors for new-onset chronic kidney disease.

Monitoring BMI can be crucial for preventing chronic kidney disease.

GLP-1 agonists had a good safety profile with most adverse effects being mild.

GLP-1 agonists can be considered a safe option for weight management in obese IBD patients.

Semaglutide has been approved by the FDA for the treatment of obesity or overweight.

Healthcare providers can prescribe semaglutide for weight management in eligible patients.

Incretin-based therapies were associated with a mean reduction in the apnea-hypopnea index (AHI) of -14.45 events/h.

Incretin-based therapies may effectively reduce AHI in OSA patients, improving sleep quality.

Incretin-based therapies showed a greater effect on AHI compared to usual care, with a mean difference of -11.61 events/h.

Incretin-based therapies may be more effective than usual care for improving AHI in OSA patients.

Tirzepatide, a GLP-1/GIP receptor co-agonist, is approved for type 2 diabetes and shows significant reductions in glycemia and body weight compared to GLP-1R mono-agonism with semaglutide.

Tirzepatide may be a more effective treatment option for managing blood sugar and weight in patients with type 2 diabetes.

All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC), HDL-C, VLDL-C, triglyceride (TG), and waist circumference (WC) changes from baseline compared with control agents.

Tirzepatide may be considered as an effective treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

Only 5 mg once-weekly tirzepatide could induce significant alteration in LDL-C before sensitivity analysis.

Clinicians should note that the 5 mg dose of tirzepatide may be more effective for lowering LDL-C compared to higher doses.